Cytek Biosciences Statistics
Share Statistics
Cytek Biosciences has 128.81M shares outstanding. The number of shares has increased by -3.56% in one year.
| Shares Outstanding | 128.81M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.18% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 116.78M |
| Failed to Deliver (FTD) Shares | 5.83K |
| FTD / Avg. Volume | 0.86% |
Short Selling Information
The latest short interest is 4.20M, so 3.26% of the outstanding shares have been sold short.
| Short Interest | 4.20M |
| Short % of Shares Out | 3.26% |
| Short % of Float | 3.59% |
| Short Ratio (days to cover) | 8.89 |
Valuation Ratios
The PE ratio is -101.56 and the forward PE ratio is 117.33.
| PE Ratio | -101.56 |
| Forward PE | 117.33 |
| PS Ratio | 6.39 |
| Forward PS | 3.4 |
| PB Ratio | 3.14 |
| P/FCF Ratio | 2717.58 |
| PEG Ratio | n/a |
Enterprise Valuation
Cytek Biosciences Inc. has an Enterprise Value (EV) of 1.10B.
| EV / Earnings | -90.49 |
| EV / Sales | 5.7 |
| EV / EBITDA | -249.39 |
| EV / EBIT | -39.48 |
| EV / FCF | 2421.42 |
Financial Position
The company has a current ratio of 6.97, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.97 |
| Quick Ratio | 5.89 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.56 |
| Cash Flow / Debt | 2.39 |
| Interest Coverage | -13.45 |
Financial Efficiency
Return on equity (ROE) is -0.03% and return on capital (ROIC) is -5.29%.
| Return on Equity (ROE) | -0.03% |
| Return on Assets (ROA) | -0.02% |
| Return on Capital (ROIC) | -5.29% |
| Revenue Per Employee | 299.25K |
| Profits Per Employee | -18.83K |
| Employee Count | 645 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.37 |
Taxes
| Income Tax | -3.56M |
| Effective Tax Rate | 0.23 |
Stock Price Statistics
The stock price has increased by -31.83% in the last 52 weeks. The beta is 1.32, so Cytek Biosciences 's price volatility has been higher than the market average.
| Beta | 1.32 |
| 52-Week Price Change | -31.83% |
| 50-Day Moving Average | 5.87 |
| 200-Day Moving Average | 5.97 |
| Relative Strength Index (RSI) | 52.01 |
| Average Volume (20 Days) | 681.74K |
Income Statement
In the last 12 months, Cytek Biosciences had revenue of $193.01M and earned -$12.15M in profits. Earnings per share was $-0.09.
| Revenue | 193.01M |
| Gross Profit | 109.43M |
| Operating Income | -27.84M |
| Net Income | -12.15M |
| EBITDA | -4.41M |
| EBIT | -27.84M |
| Earnings Per Share (EPS) | -0.09 |
Balance Sheet
The company has $167.30M in cash and $14.14M in debt, giving a net cash position of $153.16M.
| Cash & Cash Equivalents | 167.30M |
| Total Debt | 14.14M |
| Net Cash | 153.16M |
| Retained Earnings | -29.18M |
| Total Assets | 491.23M |
| Working Capital | 327.39M |
Cash Flow
In the last 12 months, operating cash flow was $5.28M and capital expenditures -$4.83M, giving a free cash flow of $454.00K.
| Operating Cash Flow | 5.28M |
| Capital Expenditures | -4.83M |
| Free Cash Flow | 454.00K |
| FCF Per Share | 0 |
Margins
Gross margin is 56.69%, with operating and profit margins of -14.43% and -6.29%.
| Gross Margin | 56.69% |
| Operating Margin | -14.43% |
| Pretax Margin | -8.14% |
| Profit Margin | -6.29% |
| EBITDA Margin | -2.28% |
| EBIT Margin | -14.43% |
| FCF Margin | 0.24% |
Dividends & Yields
CTKB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.45% |
| FCF Yield | 0.06% |
Analyst Forecast
The average price target for CTKB is $9, which is 45.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 45.4% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 5.71 |
| Piotroski F-Score | 5 |